| Document Date: 2014-11-04 04:29:08
Open Document File Size: 76,31 KBShare Result on Facebook
City Cambridge / / Company SR One / MP Healthcare Venture Management / Aescap Venture / TVM Capital / Beta Ltd. / Alpha Ltd. / Atlas Venture / Novo Ventures / Boehringer Ingelheim / Merck Serono Ventures / Bristol-Myers Squibb / / Country United Kingdom / / / Event Funding / M&A / Business Partnership / / IndustryTerm oncology-focused biopharmaceutical / biopharmaceutical / cancer therapeutics / manufacturing / therapeutic products / bispecific antibody products / / Person John Haurum / Jane Dancer / / / Position CEO / Chief Executive Officer / Chief Business Officer / dancer / CEO of F-star / / Product Beta / / Technology Alpha / Adam / 2 Technology / antibodies / / URL www.f-star.com / /
SocialTag |
F-star Announces the Formation of Second Asset-Centric Vehicle, F-star Beta Ltd F-star Beta to Develop Oncology and Immuno-Oncology Compounds Cambridge, UK, 4 NovemberF-star an oncology-focused biopharmaceutical c